3、https://www.orion.fi/en/Orion-group/media/press-releases/2022/orion-enters-into-exclusive-agreement-with-jemincare-for-novel-non-opioid-drug-candidate-for-the-treatment-of-pain/?epieditmode=true. 4、https://news.vrtx.com/news-r...
“Vertex’s willingness to drop VX-961 based on those variables reflects a belief that safety and efficacy are “table stakes--支柱” in pain. To succeed, Vertex is looking for “a molecule with the perfect PK” for the indication. That search is underpinned by an understanding of how pain...
METHODSAfter establishing the selectivity of VX-548 forNaV1.8inhibition in vitro, we conducted two phase 2 trials involving participants with acute pain after abdominoplasty or bunionectomy. In the abdominoplasty trial, participants were randomly assigned in a 1:1:1:1 ratio to receive one of th...
Jones J, Correll DJ, Lechner SM, et al. Selective Inhibition of Na1.8 with VX-548 for Acute Pain.N Engl J Med. doi:10.1056/NEJMoa2209870. 『梧桐医学』是由麻醉学(包含疼痛方向)本科、硕士、博士、博后以及刚工作的年轻医生组建的学习型...
目疼痛药物的江湖异常热闹:Vertex的进展宛如一粒顽石,冲开沉寂的水面,泛起圈圈涟漪:Vertex计划于2024年中向FDA提交VX-548的上市申请,该药物有望成为二十年来首款非阿片类的急性镇痛药物;国内的企业也是纷纷发力,近期恒瑞在2024年2月29日披露了新Nav1.8的专利,成为了全球首个VX-548的fast follower1。
目疼痛药物的江湖异常热闹:Vertex的进展宛如一粒顽石,冲开沉寂的水面,泛起圈圈涟漪:Vertex计划于2024年中向FDA提交VX-548的上市申请,该药物有望成为二十年来首款非阿片类的急性镇痛药物;国内的企业也是纷纷发力,近期恒瑞在2024年2月29日披露了新Nav1.8的专利,成为了全球首个VX-548的fast follower1。
548 into Phase 3 clinical trials in the fourth quarter of 2022.Vertexalso intends to initiate a Phase 2 dose-ranging study of VX-548 in neuropathic pain by the end of this year. In addition, the FDA has granted VX-548 Breakthrough Therapy Designation for the treatment of moderat...
参考文献: [1]. WHO Drug Information-World Health Organization (WHO). [2]. Jones J, et al. Selective Inhibition of NaV1.8 with VX-548 for Acute Pain. N Engl J Med. 2023 Aug 3;389(5):393-405.
- VX-548 advances into pivotal development for people with acute pain; Phase 3 program to initiate in Q4 2022 - - Phase 2 dose-ranging trial in neuropathic pain expected to initiate by year end - -Breakthrough Therapy Designation granted by FDA - ...
VX-548 had a more rapid onset to meaningful pain relief than placebo in both the abdominoplasty and bunionectomy trials. (The median time to meaningful pain relief was 8 hours for placebo in both studies compared to 2 hours in abdominoplasty and 4 hours in bunionectomy for VX-548,...